AirSculpt Technologies, Inc.

How big is AirSculpt Technologies, Inc.?

As of Jun 18, AirSculpt Technologies, Inc. has a market capitalization of 315.19 million and reported net sales of 172.10 million with a net profit of -17.13 million over the latest four quarters. Shareholder's funds are at 79.29 million, and total assets amount to 210.00 million.

As of Jun 18, AirSculpt Technologies, Inc. has a market capitalization of 315.19 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 172.10 million, while the sum of Net Profit for the same period is -17.13 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 79.29 million and Total Assets at 210.00 million.

What does AirSculpt Technologies, Inc. do?

AirSculpt Technologies, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $39 million and a net loss of $3 million as of March 2025. It has a market cap of $315.19 million and key metrics indicating a loss-making status with a debt-to-equity ratio of 0.98.

Overview:<BR>AirSculpt Technologies, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 39 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 315.19 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.98 <BR>Return on Equity: -12.46% <BR>Price to Book: 4.08 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold AirSculpt Technologies, Inc.?

Is AirSculpt Technologies, Inc. overvalued or undervalued?

As of August 9, 2024, AirSculpt Technologies, Inc. is considered risky and overvalued due to a negative P/E ratio, high EV to EBITDA, and poor financial metrics, with a year-to-date return of -6.55% compared to the S&P 500's 2.44%.

As of 9 August 2024, the valuation grade for AirSculpt Technologies, Inc. has moved from attractive to risky, indicating a significant shift in its financial outlook. The company is currently deemed overvalued, particularly given its negative P/E ratio and troubling financial metrics. Key ratios include a Price to Book Value of 3.85, an EV to EBITDA of 69.07, and a ROE of -12.46%. <BR><BR>In comparison to its peers, AirSculpt's financial performance appears weak; for instance, Silk Road Medical, Inc. has a P/E of -19.76 and an EV to EBITDA of -18.12, while IRadimed Corp. is in a fair position with a P/E of 37.26 and an EV to EBITDA of 29.31. The company's recent stock performance has been lackluster, with a year-to-date return of -6.55% compared to a modest 2.44% return for the S&P 500, reinforcing the notion of overvaluation amidst a challenging market environment.

Is AirSculpt Technologies, Inc. technically bullish or bearish?

As of August 29, 2025, AirSculpt Technologies, Inc. shows a mildly bullish trend with positive momentum from the MACD and daily moving averages, but mixed signals from the KST and OBV suggest cautious monitoring despite strong year-to-date and annual performance compared to the S&P 500.

As of 29 August 2025, the technical trend for AirSculpt Technologies, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the weekly KST and OBV are mildly bearish, and the Dow Theory shows a mildly bearish signal on the weekly timeframe, which adds caution to the outlook.<BR><BR>In terms of performance, the stock has returned 18.5% year-to-date compared to the S&P 500's 12.22%, and it has outperformed the S&P 500 over the past year with a return of 38.83% versus 17.14%. Overall, the current technical stance is mildly bullish, but the mixed signals suggest a need for careful monitoring.